Daily Archives: November 23, 2022

The data from your phase III randomized trials (ERASURE and FIXTURE) showed that secukinumab at doses of 300 or 150 mg is effective and safe for the treatment of moderate-to-severe psoriasis up to week 52 (Supplementary Table) (77). pathways, including canonical nuclear factor-B (NF-B), CCAAT/enhancer-binding protein (C/EBP) family, and mitogen-activated […]